Susanna V. Ulahannan

机构：Oklahoma State University Oklahoma City, University of Oklahoma Health Sciences Center, University of Oklahoma · ORCID：0000-0002-7234-2283

发表论文 265 篇 · 总被引 3570 次 · h-index 26

代表论文

• Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors (2025 · Investigational New Drugs · 被引 11)
• Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial (2026 · Nature Medicine · 被引 7)
• The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial (2025 · Clinical Cancer Research · 被引 7)
• SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer (2025 · Annals of Surgery · 被引 3)
• 938P A phase I/Ib study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations (2025 · Annals of Oncology · 被引 3)
• KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer (2026 · Cancer Research · 被引 2)